CHICAGO — Patients with diabetic macular edema maintained vision at longer injection intervals with 8 mg intravitreal aflibercept, according to a study presented at Retina Subspecialty Day at the American Academy of Ophthalmology meeting.
David M. Brown, MD, said DME levels are increasing in the United States, and the condition continues to have a high treatment burden.
“Our current VEGF drugs, although great and revolutionary, often require monthly or near monthly dosing to control diabetic macular edema,” he said.
In the phase 2/3 PHOTON study, researchers assessed the safety